|
業務類別
|
Biotechnology |
|
業務概覽
|
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. |
| 公司地址
| 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6 |
| 電話號碼
| +1 250 744-2487 |
| 傳真號碼
| +1 604 369-4115 |
| 公司網頁
| https://www.auriniapharma.com |
| 員工數量
| 128 |
| Mr. Peter S. Greenleaf |
President, Chief Executive Officer and Director |
美元 822.88K |
26/02/2026 |
| Mr. Matthew Donley |
Chief Operating Officer |
美元 539.32K |
17/04/2025 |
| Dr. Greg Keenan, M.D. |
Chief Medical Officer |
美元 495.19K |
17/04/2025 |
| Mr. Joseph M. Miller |
Chief Financial Officer and Principal Accounting Officer |
美元 500.70K |
26/02/2026 |
| Mr. Stephen P. Robertson |
Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer |
美元 471.70K |
17/04/2025 |
|
|
| Mr. Peter S. Greenleaf |
President, Chief Executive Officer and Director |
26/02/2026 |
| Mr. Craig A. Johnson |
Independent Director |
26/02/2026 |
| Mr. Jeffrey Allen Bailey |
Independent Director |
26/02/2026 |
| Mr. Kevin C. Tang |
Chairman of the Board |
26/02/2026 |
|
|
|
|
